Notes to the Consolidated Financial Statements for the Year Ended 30 June 2014 Benitec Biopharma Ltd  Annual Report 2014 Page 29 2014 2013 $ $ Loss after income tax used in the calculation of basic EPS and dilutive EPS  (7,039,109)  (3,487,960) Number Number Weighted average number of ordinary shares for basic and diluted earnings per share  90,432,177 41,688,975  Weighted average number of converted, lapsed or cancelled potential ordinary shares included in diluted earnings per share  - -  2014 2013 $ $ NOTE 5: AUDITOR’S REMUNERATION Audit Services Remuneration of Grant Thornton Audit Pty Ltd for:  - auditing or reviewing the financial report  73,238  54,000 Other Services Remuneration of Grant Thornton Australia Limited for: - taxation compliance and corporate advisory services  24,000  43,230 Outstanding options to acquire ordinary shares are not considered dilutive for the years ended 30 June 2014 and 30 June 2013. No securities or convertible debt instruments could be classified as potential ordinary shares under AASB 133 and therefore have not been  included in determination of dilutive EPS. Classification of securities NOTE 6: EARNINGS PER SHARE  Basic earnings per share is calculated by dividing the net loss for the year attributable to ordinary shareholders by the weighted average number  of ordinary shares on issue during the year. Diluted earnings per share amounts are calculated by dividing the net loss attributable to ordinary shareholders by the weighted average number  of ordinary shares on issue during the year (adjusted for the effects of dilutive options) and the weighted average number of ordinary shares that  would be issued on conversion of all dilutive potential ordinary shares. (b) The parent entity, acting as the Head Entity, notified the Australian Taxation Office on 12 February 2004 that it had formed a Tax Consolidated  Group applicable as from 1 July 2002. No tax sharing agreement has been entered between entities in the tax consolidated group. (c) As at 30 June 2014, the Tax Consolidated Group has estimated carry-forward tax losses of $13,103,412 (2013: $11,751,713) calculated at 30%  of the accumulated annual Australian tax losses. The tax losses have not been recognised in the financial statements and the capacity of the  Tax Consolidated Group to use the tax losses will be subject to conforming with regulatory tests. The deferred tax asset relating to temporary  differences (calculated at 30%) was $49,953 (2013: $29,591).  The Tax Consolidated Group also has Australian capital tax losses for which no deferred tax asset is recognised in the financial statements  of $381,588 (2013: $381,588). The capacity of the Tax Consolidated Group to use the capital tax losses will be subject to conforming with  regulatory tests. The recoupment of available tax losses as at 30 June 2014 is contingent upon the following: (i)  the Consolidated Group deriving future assessable income of a nature and of an amount sufficient to enable the benefit from the losses to  be realised; (ii) the conditions for deductibility imposed by tax legislation continuing to be complied with; and (iii) there being no changes in tax legislation which would adversely affect the Tax Consolidated Group from realising the benefit from the losses.